 | |
| Clinical data | |
|---|---|
| Trade names | Junoenil |
| Other names | EVT-201 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H17ClN6O2 |
| Molar mass | 372.81 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Dimdazenil (trade nameJunoenil) is a pharmaceutical drug forinsomnia.[1] It is abenzodiazepinederivative and a partialpositive allosteric modulator of the GABAA receptor[2] with two- to four-fold higher functionalaffinity for theα1 subunit relative to theα2,α3, andα5 subunits.
Dimdazenil shows effectiveness in the treatment ofinsomnia, but has lessintrinsic activity in comparison to currently-marketed benzodiazepines and theZ-drugs;[3] however, it is thought that the lower efficacy may result in fewerside effects, such asmotor incoordination.[3] In China, dimdazenil is approved for short-term treatment of insomnia.[4]
Dimdazenil was originally developed byRoche, based onpreclinical data, as a non-sedatinganxiolytic, but was found to producesedation in humans inphase Iclinical trials. For this reason, it was subsequently licensed toEvotec, which is now developing it for the treatment of insomnia.[3] By 2007, dimdazenil completedphase II clinical trials for this indication, with positive findings reported.[5] In China, the drug was developed by Zhejiang Jingxin Pharmaceutical.
